كندا - الإنجليزية - Health Canada

auro pharma inc - valganciclovir (valganciclovir hydrochloride) - tablet - 450mg - valganciclovir (valganciclovir hydrochloride) 450mg - nucleosides and nucleotides

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

american health packaging - valganciclovir hydrochloride (unii: 4p3t9qf9nz) (ganciclovir - unii:p9g3ckz4p5) - treatment of cytomegalovirus (cmv) retinitis: valganciclovir for oral solution is indicated for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome (aids) [see clinical studies (14.1)]. prevention of cmv disease: valganciclovir for oral solution is indicated for the prevention of cmv disease in kidney, heart, and kidney-pancreas transplant patients at high risk (donor cmv seropositive/recipient cmv seronegative [d+/r-]) [see clinical studies (14.1)]. prevention of cmv disease: valganciclovir for oral solution is indicated for the prevention of cmv disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk [see clinical studies (14.2)]. valganciclovir for oral solution is contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valganciclovir, ganciclovir, or any component of the formulation [see adv

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - valganciclovir hydrochloride -

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - valganciclovir hydrochloride -

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - valganciclovir hydrochloride -

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - valganciclovir hydrochloride -

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - valganciclovir, quantity: 5 g - solution, powder for - excipient ingredients: mannitol; fumaric acid; sodium benzoate; saccharin sodium; povidone; flavour - valcyte is indicated for the treatment of cytomegalovirus (cmv) retinitis in adult patients with acquired immunodeficiency syndrome (aids). valcyte is indicated for the prophylaxis of cmv disease in adult and paediatric solid organ transplantation (sot) patients who are at risk.

بلجيكا - الإنجليزية - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cheplapharm arzneimittel gmbh - valganciclovir hydrochloride 496,3 mg - eq. valganciclovir 450 mg - film-coated tablet - 450 mg - valganciclovir hydrochloride 496.3 mg - valganciclovir

المملكة المتحدة - الإنجليزية - myHealthbox

milpharm limited - valganciclovir - film-coated tablets - 450mg - antivirals for systemic use, nucleosides and nucleotides excl. reverse transcriptase inhibitors - it is indicated for the induction and maintenance treatment of cytomegalovirus (cmv) retinitis in adult patients with acquired immunodeficiency syndrome (aids) and for the prevention of cmv disease in cmvnegative adults and children (aged from birth to 18 years) who have received a solid organ transplant from a cmv-positive donor.

بلجيكا - الإنجليزية - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - valganciclovir hydrochloride 496,3 mg - eq. valganciclovir 450 mg - film-coated tablet - valganciclovir